In case you missed it, the Institute for Clinical and Economic Review (ICER) is seeking suggestions to improve its value assessment framework prior to its re-release in 2017. For the past two years, ICER has been issuing assessment reports that raise significant concerns about the impact on patient access to medicines and continued medical progress. In response, ICER has received significant feedback from stakeholders across the health care spectrum.PhRMA supports the development of rigorous, patient-centered decision-support tools and definitions of value that reflect the full range of stakeholder perspectives, and we appreciate ICER’s openness to improving its approach.
PhRMA submitted comments on ICER’s original framework last October, and has since established principles for value assessment frameworks. A growing number of patients, providers and other stakeholders have also been providing feedback to ICER. Comments submitted in response to reports on treatments for multiple myeloma and non-small cell lung cancer by patient and provider groups have underscored shortcomings in ICER’s methods and assumptions, lacked transparency and failed to reflect the complex realities of optimally caring for patients with devastating and debilitating conditions.
We encourage stakeholders to answer ICER’s call for feedback. ICER is accepting comments through Friday, September 12, 2016. Learn more here.